Adalimumab was a first fully humanized monoclonal antibody approved by US Food and Drug Administration (FDA) in 2002. Clinical efficacy and safety of adalimumab has been assessed in various trials in rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. It is one of the major sales success among biological and still one of the greatest blockbuster amongst monoclonal antibodies.
Based on the Adalimumab Biosimilar market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.
In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.
Key players in the global Adalimumab Biosimilar market covered in Chapter 5:
Boehringer Ingelheim
Sandoz
LG Life Sciences/Mochida Pharmaceutical
Fujifilm Kyowa Kirin Biologics
Pfizer
Oncobiologics
Momenta Pharmaceuticals
Zydus Cadila
Amgen
AET BioTech
Samsung Bioepsis
Coherus Biosciences
In Chapter 6, on the basis of types, the Adalimumab Biosimilar market from 2015 to 2025 is primarily split into:
Exemptia
Adalirel
Cipleumab
Others
In Chapter 7, on the basis of applications, the Adalimumab Biosimilar market from 2015 to 2025 covers:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
Summary:
Get latest Market Research Reports on Adalimumab Biosimilar. Industry analysis & Market Report on Adalimumab Biosimilar is a syndicated market report, published as Global Adalimumab Biosimilar Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery. It is complete Research Study and Industry Analysis of Adalimumab Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.